Last reviewed · How we verify
NCT06585761
Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients
trial testing SGLT2 inhibitor in Heart Failure in 60 participants. Currently enrolling.
30 June 2025
Quick facts
| Lead sponsor | Kafrelsheikh University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 15 February 2024 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- SGLT2 inhibitor — full drug profile →
- echo cardiogram
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Kafrelsheikh University
Who can join
Adults 18 to 80, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to explore the effect of SGLT2i on the levels of cardiac biomarkers, inflammatory and stress markers in Egyptian heart failure patients to provide a better understanding of mechanism that might assist in tailoring treatment strategies in patients with various forms of HF especially in Egyptian population. Also understand how biomarkers may be employed to predict risk in patients receiving SGLT2i or identification of those who may derive the most benefit from SGLT2i in the means of individualized medicine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06585761
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SGLT2 inhibitor
Trials testing the same drug.
- NCT07360457 — GLP1 Analogues and the Risk of Osteoarthritis · not yet recruiting
- NCT07172971 — Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy · Phase 1 · not yet recruiting
- NCT07334145 — Effect of SGLT2 Inhibitors on Anemic CKD Patients · not yet recruiting
- NCT07063316 — SGLT2 Inhibitors and Renal Anemia in Japan: RWD · active not recruiting
- NCT06350487 — The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction · Phase 4 · not yet recruiting
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Kafrelsheikh University trials
Trials by the same sponsor.
- NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
- NCT07433920 — L-PRF Versus Sticky Bone Grafting of the Jumping Gap in AI-assisted Computer-Guided Socket Shield Immediate Implantation · NA · recruiting
- NCT07368348 — Evaluation of Internal Nasal Splint-Supported Free Graft Versus Nasoseptal Flap for Endoscopic Skull Base Repair in Cere · NA · recruiting
- NCT07348094 — Guided Lateral Sinus Lifting Using Autologous Serum Albumin/Platelet-Rich Fibrin · NA · recruiting
- NCT07359144 — Pilates Exercises on Nonspecific Low Back Pain in Postnatal Women · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06585761 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kafrelsheikh University
- Last refreshed: 5 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06585761.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing